EP2822590
IL-17-mótefnissamsetning
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
1.3.2013EP published:
26.10.2016EP application number:
13710214.1
EP translation filed:
30.11.2016Grant published:
15.12.2016EPO information:
European Patent Register
Max expiry date:
28.2.2033Expiry date:
28.2.2027Next due date:
28.3.2027
Title:
IL-17 ANTIBODY FORMULATION
Timeline
Today
1.3.2013EP application
26.10.2016EP Publication
30.11.2016Translation submitted
15.12.2016Registration published
28.2.2027Expires
Owner
Name:
Eli Lilly and CompanyAddress:
Lilly Corporate Center, 46285, Indianapolis, IN, US
Inventor
Name:
CORVARI, Vincent, JohnAddress:
IndianapolisIndiana, US
Name:
WILLIAMS, Barbara, AnnAddress:
IndianapolisIndiana, US
Name:
DONOVAN, Patrick, DanielAddress:
IndianapolisIndiana, US
Name:
MARKHAM, Aaron, PaulAddress:
IndianapolisIndiana, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201261607671 PDate:
7.3.2012Country:
US
Classification
Categories:
A61K 39/395, C07K 16/24
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 3.1.2017
Expires: 28.2.2018
Payer: Árnason Faktor
Number: 6
Paid: 12.2.2018
Expires: 28.2.2019
Payer: Örn Þór, slf.
Number: 7
Paid: 14.2.2019
Expires: 28.2.2020
Payer: Örn Þór, slf.
Number: 8
Paid: 14.2.2020
Expires: 28.2.2021
Payer: Örn Þór slf.
Number: 9
Paid: 17.2.2021
Expires: 28.2.2022
Payer: Patice ehf.
Number: 10
Paid: 17.2.2022
Expires: 28.2.2023
Payer: Patice ehf.
Number: 11
Paid: 22.2.2023
Expires: 28.2.2024
Payer: Árnason Faktor ehf.
Number: 12
Paid: 29.2.2024
Expires: 28.2.2025
Payer: Árnason Faktor ehf.
Number: 13
Paid: 21.2.2025
Expires: 28.2.2026
Payer: Árnason Faktor ehf.
Number: 14
Paid: 5.3.2026
Expires: 28.2.2027
Payer: Árnason Faktor ehf.